Selected data models

You must log in to select data models for download or further analysis.

32 Search results.
Relevance Rating New first Old first

Eligibility Mature B-Cell Lymphoma NCT01046825

- 9/27/21 - 1 form, 2 itemgroups, 25 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Mature B-Cell Lymphoma And Leukemia Study III; ODM derived from: https://clinicaltrials.gov/show/NCT01046825

Eligibility Lymphoma, B-Cell NCT00515138

- 9/20/21 - 1 form, 2 itemgroups, 21 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Pilot Study of Standard-Dose Rituximab, Ifosfamide, Carboplatin and Etoposide (RICE) Plus Bortezomib (Velcade) in a Dose-Escalating Fashion for Patients With Relapsed or Primary Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma Who Are Candidates for Autologous Stem Cell Transplant; ODM derived from: https://clinicaltrials.gov/show/NCT00515138

Eligibility Ocular Adnexal Mucosa-Associated Lymphoid Tissue Lymphoma NCT01514344

- 6/20/21 - 1 form, 2 itemgroups, 12 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Intralesional Rituximab for the Treatment of Conjunctival Indolent Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT01514344

Eligibility Lymphoma, B-Cell, Non-Hodgkin's Lymphoma NCT01724021

- 7/22/20 - 1 form, 2 itemgroups, 19 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Study of Patient Preference With Subcutaneous Versus Intravenous MabThera/Rituxan (Rituximab) in Patients With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3a; ODM derived from: https://clinicaltrials.gov/show/NCT01724021

Eligibility Lymphoma, B-Cell, Lymphoma, Follicular NCT01691898

- 7/22/20 - 1 form, 2 itemgroups, 16 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Study of DCDT2980S in Combination With MabThera/Rituxan or DCDS4501A in Combination With MabThera/Rituxan and Evaluation of Combination DCDS4501A and Obinutuzumab in Patients With Non-Hodgkin's Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT01691898

Eligibility Lymphoma, B-Cell NCT02017613

- 7/21/20 - 1 form, 2 itemgroups, 14 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in Hematological Malignancies; ODM derived from: https://clinicaltrials.gov/show/NCT02017613

Eligibility Lymphoma, B-Cell NCT01649856

- 7/21/20 - 1 form, 2 itemgroups, 17 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Study of Subcutaneous Versus Intravenous MabThera/Rituxan (Rituximab) in Combination With CHOP Chemotherapy in Patients With Previously Untreated CD20-Positive Diffuse Large B-Cell Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT01649856

Eligibility Lymphoma, B-Cell NCT01287741

- 7/20/20 - 1 form, 2 itemgroups, 16 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Study of Obinutuzumab (RO5072759) in Combination With CHOP Chemotherapy Versus MabThera/Rituxan (Rituximab) With CHOP in Patients With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA); ODM derived from: https://clinicaltrials.gov/show/NCT01287741

Eligibility Lymphoma, B-Cell NCT01144403

- 7/18/20 - 1 form, 2 itemgroups, 11 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Study of MabThera (Rituximab) Addition to Regularly Prescribed Chemotherapy in Patients With Untreated Mantle Cell Lymphoma.; ODM derived from: https://clinicaltrials.gov/show/NCT01144403

Eligibility Low Grade B Cell Lymphoma NCT01289210

- 7/6/20 - 1 form, 2 itemgroups, 13 items, 1 language
Itemgroups: Criteria, Exclusion Criteria
VTX-2337 in Combination With Radiotherapy in Patients Low-Grade B-cell Lymphomas; ODM derived from: https://clinicaltrials.gov/show/NCT01289210

Eligibility Indolent B-cell Non-Hodgkin's Lymphoma NCT01933516

- 5/1/20 - 1 form, 2 itemgroups, 9 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
GP2013 in Japanese Patients With CD20 Positive Low Tumor Burden Indolent B-cell Non-Hodgkin's Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT01933516

Eligibility B-cell Non Hodgkin's Lymphoma NCT02206308

- 8/19/19 - 1 form, 2 itemgroups, 15 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Safety, Pharmacokinetics and Pharmacodynamics of Recombinant Chimeric Anti-CD20 Monoclonal Antibody in Patients With B-cell Non-Hodgkin's Lymphoma.; ODM derived from: https://clinicaltrials.gov/show/NCT02206308

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial